Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2020

View Archived Issues

How hook(worm)s grapple with nets

Heat-shock proteins' subtler cousin

GLP1R agonist-DYRK1A inhibitor combination enhances beta cell proliferation with better specificity

AGAP2-AS1 as a new biomarker to identify low-risk progressors in ccRCC

Immunotherapy with pembrolizumab plus HER2 BATs shows promise in mCRPC

Dose-escalation data presented from phase Ib/II study of cetrelimab plus erdafitinib in mUC

First patient enrolled in phase II study of PL-9643 for the treatment of dry eye

Terns Pharmaceuticals completes phase I study of TERN-101

First subject dosed in phase I study of TAK-169 in multiple myeloma

resTORbio presents interim phase Ib/IIa data for RTB-101 in PD along with corporate update

Mitsubishi Tanabe Pharma describes new autotaxin inhibitors

APOBEC3B predicts good prognosis with gemcitabine plus platinum therapy in patients with mUC

Mutabilis discovers bacterial beta-lactamase inhibitors

New HDAC inhibitors disclosed by Merck & Co.

Lilly identifies new O-GlcNAcase inhibitors

STING agonists patented by Incyte

Progress in Human Cell Atlas unveiling underlying mechanisms of disease

TUBB3 predicts prognosis in patients with metastatic prostate cancer under abiraterone therapy

GeneTX recruits pediatric patients with Angelman syndrome for phase I/II study of GTX-102

Immutep reports interim data from phase II study of eftilagimod alpha in NSCLC and HNSCC

New phase I trial evaluates safety and immunogenicity of dengusiil

[68Ga]PSMA-11 PET/CT has a large effect on prostate cancer staging and management

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...